Government health officials just approved the first new drug for Alzheimer’s disease in nearly 20 years even though independent advisers have said treatment hasn’t been shown to help slow the brain-destroying disease. The FDA said it granted the drug's approval from Biogen based on results that seemed “reasonably likely” to benefit Alzheimer’s patients. This is the only drug that U.S. regulators have said can likely treat the underlying disease rather than just managing symptoms. While the new drug did not reverse mental decline, it did slow it in one study. The medication, aducanumab, will be marketed as Aduhelm and will be given as an infusion every four weeks. The FDA is requiring Biogen to conduct a follow-up study to confirm benefits for patients. If the study fails to show effectiveness, the FDA could pull the drug from the market.
Photo Credit: Getty Images